Related Experiment Video

Updated: Jun 3, 2026

A Pre-Clinical Porcine Model of Orthotopic Heart Transplantation
09:12

A Pre-Clinical Porcine Model of Orthotopic Heart Transplantation

Published on: April 27, 2019

[Outcome post orthotopic heart transplantation for patients with end-stage hypertrophic cardiomyopathy]

Xue-shan Huang1, Liang-wan Chen, Yu-chen Pan

  • 1Department of Cardiac Surgery, Fujian Medical University, Fuzhou 350001, China. drhxs@163.com

Zhonghua Xin Xue Guan Bing Za Zhi
|March 24, 2011
PubMed

Insights

Orthotopic heart transplantation offers a successful treatment for end-stage hypertrophic cardiomyopathy. Most patients experience good quality of life post-transplant, highlighting its therapeutic value.

Area of Science:

  • Cardiology
  • Transplantation Medicine
  • Immunology

Context:

  • Hypertrophic cardiomyopathy (HCM) is a significant cause of heart failure.
  • End-stage HCM often necessitates advanced treatment options.
  • Orthotopic heart transplantation (OHT) is a potential solution for end-stage heart disease.

Purpose:

  • To evaluate the outcomes of OHT in patients with end-stage HCM.
  • To assess the efficacy and safety of OHT in this specific patient population.

Summary:

  • This retrospective study reviewed nine patients with end-stage HCM who underwent OHT.
  • Eight patients survived with good quality of life, experiencing no significant rejection or infection.
  • One patient experienced complications including renal failure and died at 32 months; another developed demyelinating disease but recovered.

Impact:

  • OHT is a viable and effective therapeutic option for carefully selected patients with end-stage HCM.
  • The study demonstrates favorable long-term outcomes for most OHT recipients with HCM.
  • Findings support OHT as a life-saving intervention, improving quality of life in advanced HCM.
Abstract

More Related Videos

Implantation of the Syncardia Total Artificial Heart16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

Implantation of Total Artificial Heart in Congenital Heart Disease07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...